



Address: HSL-AD, Ground Floor, 60 Whitfield Street, London, W1T 4EU

Tel: +44 (0)20 3912 0280 | Email: AD@hslpathology.com | Web: www.hsl-ad.com

QC	INITIALS	DATE
Cut		
Labelled		
Collated		
QC		
Packaged		

## PD-L1 IHC (PEMBROLIZUMAB, Agilent pharmDx 22C3, NSCLC, TPS)

### FOR LABORATORY USE ONLY

HSL-AD NUMBER: \_\_\_\_\_ MATERIAL RECEIVED: \_\_\_\_\_

PRICE (TO BE INVOICED): \_\_\_\_\_ DATE RECEIVED & INITIALS: \_\_\_\_\_

### PATIENT / SAMPLE DETAILS

SURNAME: \_\_\_\_\_ SURGICAL CASE ID: \_\_\_\_\_

FORENAME: \_\_\_\_\_ TUMOUR TYPE & GRADE: \_\_\_\_\_

DOB: \_\_\_\_\_ **M** **F**

### REFERRING HOSPITAL / INVOICING DETAILS

CONSULTANT: \_\_\_\_\_

ADDRESS: \_\_\_\_\_

PHONE: \_\_\_\_\_

#### INVOICING DETAILS (if different)

CONTACT NAME: \_\_\_\_\_

ORGANISATION: \_\_\_\_\_

ADDRESS: \_\_\_\_\_

PURCHASE NUMBER: \_\_\_\_\_

REPORT DELIVERY (please tick - faxing of reports will end October 2020)

FAX

EMAIL

FAX NUMBER(S):

EMAIL ADDRESS(ES):

## PD-L1 (PEMBROLIZUMAB, AGILENT 22C3 pharmDx, NSCLC) TPS IHC REPORT

### TUMOUR ASSESSMENT

- SUFFICIENT FOR ASSESSMENT  
 INSUFFICIENT FOR ASSESSMENT

### INTENSITY OF STAINING

- % 3+  
 % 2+  
 % 1+  
 % 0

### RESULT

- % OF TOTAL TUMOUR CELLS EXPRESSING PD-L1 (TPS)  
  
 **NEGATIVE** (<1% EXPRESSION)  
 **WEAK POSITIVE** (≥1% <50% EXPRESSION)  
 **STRONG POSITIVE** (≥50% EXPRESSION)

### TEST COMMENTS

**INTERPRETATION GUIDE:** This assay is FDA-approved and uses the Dako pharmDx 22C3 kit stained on the Dako Autostainer Link48. This report is for use in NSCLC only and is used as a companion diagnostic to indicate the suitability of patient treatment with Pembrolizumab. Scoring method used is the Tumour Percentage Score (TPS). Use of this report for selection of treatment options in other tumour settings has not been validated.

**NEGATIVE (<1%):** Patient is not eligible for treatment involving Pembrolizumab.

**WEAK POSITIVE (≥1% <50%):** Patient is eligible for treatment involving Pembrolizumab if they have had at least one prior chemotherapy regime. Patients with sensitising EGFR mutations or ALK rearrangement should be treated for these prior to receiving Pembrolizumab.

**STRONG POSITIVE (≥50%):** Treatment-naive patients with metastatic NSCLC are eligible for treatment with Pembrolizumab as a front-line therapy.

SIGNED: \_\_\_\_\_

DATE: \_\_\_\_\_

Dr Manuel Rodriguez-Justo / Dr Teresa Marafioti / Dr Ian Proctor